Galectin Therapeutics Inc.
GALTGalectin Therapeutics Inc. in brief
Galectin Therapeutics Inc. is a listed company in the Biotechnology industry, based in Norcross, Georgia, USA. It was founded in 2000. Its market value was $357 M on 29 October 2026, which makes it the 14,029th largest listed company in the world and the 2,748th largest in the USA on this site. Joel Lewis is its chief executive. Its shares trade under the symbol GALT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Galectin Therapeutics Inc.
We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectin proteins have a demonstrated role in the pathogenesis of a given disease. We focus on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and certain cancer indications. Our strategy is to establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when one of our programs becomes advanced and requires significant additional resources.
From the company's annual report filed with the US SEC: read the report
Galectin Therapeutics Inc. timeline
- 2000
- 🏁· approximateFounded
- 2001
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- ✎Renamed Galectin Therapeutics IncFormerly Pro Pharmaceuticals Inc.
Events of Galectin Therapeutics Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,390 (Jan 2020) · #3,525 (Jan 2021) · #4,224 (Jan 2022) · #4,530 (Dec 2022) · #4,323 (Jul 2023) · #3,668 (Jan 2024) · #1,704 (Mar 2026) · #2,761 (Aug 2026) · #2,721 (Oct 2026) · #2,752 (Oct 2026)
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-20M | $-31M | — |
| Dec 2024 | — | — | $-42M | $-47M | — |
| Dec 2023 | — | — | $-38M | $-41M | — |
| Dec 2022 | — | — | $-38M | $-39M | — |
| Dec 2021 | — | — | $-30M | $-31M | — |
| Dec 2020 | — | — | $-23M | $-23M | — |
| Dec 2019 | — | — | $-13M | $-13M | — |
| Dec 2018 | — | — | $-14M | $-14M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-24M | — | — | $-0.48 | — |
| Dec 2024 | $-42M | — | — | $-0.76 | — |
| Dec 2023 | $-33M | — | — | $-0.74 | — |
| Dec 2022 | $-31M | — | — | $-0.65 | — |
| Dec 2021 | $-24M | — | — | $-0.52 | — |
| Dec 2020 | $-21M | — | — | $-0.41 | — |
| Dec 2019 | $-11M | — | — | $-0.39 | — |
| Dec 2018 | $-10M | — | — | $-0.38 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 13, 2026DEF 14AProxy statement
- Aug 14, 20268-KCurrent reportResults of operations
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 4, 20268-KCurrent reportUnregistered share sale
- Jun 23, 20268-KCurrent reportRegulation FD disclosure
- May 15, 20268-KCurrent reportResults of operations
- May 15, 202610-QQuarterly report · period to Mar 2026
- Mar 31, 20268-KCurrent reportResults of operations
- Mar 31, 202610-KAnnual report · period to Dec 2025
- Mar 17, 20268-KCurrent reportDirectors or officers changed
- Jan 21, 20268-KCurrent reportDirectors or officers changed
- Jan 12, 20268-KCurrent reportDirectors or officers changed
Official filings of Galectin Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-20 M
- Net income
- $-31 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $20 M
- Total liabilities
- $146 M
- Total equity
- $-128 M
As of December-2025
Top 100 institutional investors in Galectin Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3,378,655 | +390,302 (+13.06%) | 3.35% | $13 M | Nov 13, 2026 |
| 2 | Vanguard Capital Management LLC | 2,092,246 | -75,819 (-3.50%) | 2.07% | $8 M | Nov 13, 2026 |
| 3 | Geode Capital Management, LLC | 1,246,559 | -61,835 (-4.73%) | 1.24% | $5 M | Nov 6, 2026 |
| 4 | Osaic Holdings, Inc. | 1,210,176 | +6,451 (+0.54%) | 1.20% | $5 M | Nov 12, 2026 |
| 5 | State Street Corp | 800,812 | +233,033 (+41.04%) | 0.79% | $3 M | Nov 12, 2026 |
| 6 | Wealthspire Advisors, LLC | 721,788 | 0 (0.00%) | 0.72% | $3 M | Nov 13, 2026 |
| 7 | Corient Private Wealth LP | 541,797 | New | 0.54% | $2 M | Nov 16, 2026 |
| 8 | Marshall Wace, LLP | 467,417 | -363,593 (-43.75%) | 0.46% | $2 M | Nov 13, 2026 |
| 9 | Commonwealth Equity Services, LLC | 460,296 | +53,183 (+13.06%) | 0.46% | $2 M | Nov 2, 2026 |
| 10 | Northern Trust Corp | 375,956 | -10,589 (-2.74%) | 0.37% | $1 M | Nov 16, 2026 |
| 11 | Vanguard Portfolio Management LLC | 333,601 | +5,835 (+1.78%) | 0.33% | $1 M | Nov 13, 2026 |
| 12 | Vanguard Fiduciary Trust Co | 333,553 | -32,923 (-8.98%) | 0.33% | $1 M | Nov 13, 2026 |
| 13 | LPL Financial LLC | 285,380 | 0 (0.00%) | 0.28% | $1 M | Nov 6, 2026 |
| 14 | Sovran Advisors, LLC | 251,544 | -6,453 (-2.50%) | 0.25% | $1 M | Nov 2, 2026 |
| 15 | Geneos Wealth Management Inc. | 237,691 | -2,736 (-1.14%) | 0.24% | $1 M | Nov 9, 2026 |
| 16 | Retirement Guys Formula LLC | 220,553 | +9,500 (+4.50%) | 0.22% | $1 M | Oct 26, 2026 |
| 17 | UBS Group AG | 213,403 | -5,916 (-2.70%) | 0.21% | $1 M | Nov 10, 2026 |
| 18 | Citadel Advisors LLC | 190,501 | -8,200 (-4.13%) | 0.19% | $1 M | Nov 16, 2026 |
| 19 | Charles Schwab Investment Management Inc | 171,783 | +55,359 (+47.55%) | 0.17% | $1 M | Nov 16, 2026 |
| 20 | Blair William & Co/il | 149,283 | 0 (0.00%) | 0.15% | $1 M | Nov 10, 2026 |
| 21 | Gsa Capital Partners LLP | 146,566 | +17,902 (+13.91%) | 0.15% | $1 M | Nov 16, 2026 |
| 22 | Goldman Sachs Group Inc | 138,558 | +64,004 (+85.85%) | 0.14% | $1 M | Nov 16, 2026 |
| 23 | Cambridge Investment Research Advisors, Inc. | 130,384 | -130,912 (-50.10%) | 0.13% | $1 M | Nov 2, 2026 |
| 24 | Morgan Stanley | 127,598 | +34,123 (+36.50%) | 0.13% | $0 M | Nov 13, 2026 |
| 25 | National Bank Of Canada /fi/ | 119,300 | -48,600 (-28.95%) | 0.12% | $0 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Renaissance Technologies LLC | 110,575 | +67,232 (+155.12%) | 0.11% | $0 M | Nov 12, 2026 |
| 27 | Bank of New York Mellon Corp | 108,367 | +2,625 (+2.48%) | 0.11% | $0 M | Nov 5, 2026 |
| 28 | Two Sigma Investments, LP | 101,748 | -216,497 (-68.03%) | 0.10% | $0 M | Nov 16, 2026 |
| 29 | HighTower Advisors, LLC | 94,760 | +635 (+0.67%) | 0.09% | $0 M | Nov 10, 2026 |
| 30 | Creative Planning | 87,499 | +76,960 (+730.24%) | 0.09% | $0 M | Nov 2, 2026 |
| 31 | Nuveen, LLC | 71,721 | +8,011 (+12.57%) | 0.07% | $0 M | Nov 10, 2026 |
| 32 | Hopwood Nicholas Hunter | 69,270 | -25 (-0.04%) | 0.07% | $0 M | Nov 13, 2026 |
| 33 | Truist Financial Corp | 68,000 | 0 (0.00%) | 0.07% | $0 M | Oct 30, 2026 |
| 34 | Bank Of America Corp /de/ | 65,087 | +7,372 (+12.77%) | 0.06% | $0 M | Nov 16, 2026 |
| 35 | Rhumbline Advisers | 52,505 | +4,173 (+8.63%) | 0.05% | $0 M | Nov 10, 2026 |
| 36 | Horizon Kinetics Asset Management LLC | 42,452 | -4,516 (-9.62%) | 0.04% | $0 M | Nov 12, 2026 |
| 37 | Deutsche Bank AG\ | 42,389 | -5,014 (-10.58%) | 0.04% | $0 M | Nov 6, 2026 |
| 38 | Pinnacle Financial Partners, Inc. | 41,650 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 39 | Price T Rowe Associates Inc /MD/ | 39,313 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 40 | Sanctuary Advisors, LLC | 36,983 | -4,747 (-11.38%) | 0.04% | $0 M | Nov 13, 2026 |
| 41 | Jpmorgan Chase & Co | 35,741 | -1,447 (-3.89%) | 0.04% | $0 M | Nov 12, 2026 |
| 42 | Pekin Hardy Strauss, Inc. | 30,000 | 0 (0.00%) | 0.03% | $0 M | Nov 2, 2026 |
| 43 | Squarepoint Ops LLC | 28,193 | New | 0.03% | $0 M | Nov 9, 2026 |
| 44 | Invesco Ltd. | 26,283 | +591 (+2.30%) | 0.03% | $0 M | Nov 12, 2026 |
| 45 | Solutions 4 Wealth, Ltd | 25,027 | 0 (0.00%) | 0.02% | $0 M | Nov 3, 2026 |
| 46 | Gladstone Institutional Advisory LLC | 23,900 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 47 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 23,248 | +1,182 (+5.36%) | 0.02% | $0 M | Nov 16, 2026 |
| 48 | Cahaba Wealth Management, Inc. | 21,000 | 0 (0.00%) | 0.02% | $0 M | Oct 26, 2026 |
| 49 | Mariner, LLC | 19,360 | +860 (+4.65%) | 0.02% | $0 M | Nov 12, 2026 |
| 50 | Stratos Wealth Partners, LTD. | 19,088 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 51 | Barclays PLC | 18,773 | +7,196 (+62.16%) | 0.02% | $0 M | Nov 6, 2026 |
| 52 | Wells Fargo & Company/mn | 18,337 | -28,354 (-60.73%) | 0.02% | $0 M | Nov 16, 2026 |
| 53 | Vanguard Global Advisers, LLC | 18,283 | +218 (+1.21%) | 0.02% | $0 M | Nov 13, 2026 |
| 54 | Archer Investment Corp | 17,501 | -17,301 (-49.71%) | 0.02% | $0 M | Nov 5, 2026 |
| 55 | Wealth Enhancement Advisory Services, LLC | 17,161 | +609 (+3.68%) | 0.02% | $0 M | Oct 13, 2026 |
| 56 | Focus Partners Wealth | 16,427 | New | 0.02% | $0 M | Nov 12, 2026 |
| 57 | MetLife Investment Management, LLC | 15,818 | -13,057 (-45.22%) | 0.02% | $0 M | Nov 16, 2026 |
| 58 | FMR LLC | 15,439 | +2,298 (+17.49%) | 0.02% | $0 M | Nov 10, 2026 |
| 59 | Raymond James Financial Inc | 14,957 | +740 (+5.21%) | 0.01% | $0 M | Nov 12, 2026 |
| 60 | Belpointe Asset Management LLC | 14,139 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 61 | Fortis Capital Advisors, LLC | 14,139 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 62 | Police & Firemen's Retirement System of New Jersey | 14,133 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 63 | New York State Common Retirement Fund | 13,600 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 64 | Sig Brokerage, LP | 13,596 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 65 | Quadrature Capital Ltd | 13,441 | New | 0.01% | $0 M | Nov 13, 2026 |
| 66 | Argyle Capital Partners, LLC | 13,375 | 0 (0.00%) | 0.01% | $0 M | Oct 23, 2026 |
| 67 | BNP Paribas Financial Markets | 12,601 | +2,385 (+23.35%) | 0.01% | $0 M | Nov 12, 2026 |
| 68 | Berkshire Money Management, Inc. | 11,349 | New | 0.01% | $0 M | Oct 21, 2026 |
| 69 | Alliancebernstein L.P. | 11,200 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 70 | WINTON GROUP Ltd | 11,200 | New | 0.01% | $0 M | Nov 12, 2026 |
| 71 | Cetera Investment Advisers | 10,828 | +828 (+8.28%) | 0.01% | $0 M | Nov 13, 2026 |
| 72 | Stock Yards Bank & Trust Co | 10,500 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 73 | Integrated Wealth Concepts LLC | 10,012 | +12 (+0.12%) | 0.01% | $0 M | Nov 17, 2026 |
| 74 | Atwood & Palmer Inc | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 8, 2026 |
| 75 | Simplex Trading, LLC | 9,720 | -73,531 (-88.32%) | 0.01% | $0 M | Nov 4, 2026 |
| 76 | Rockefeller Capital Management L.P. | 8,864 | +4,478 (+102.10%) | 0.01% | $0 M | Nov 13, 2026 |
| 77 | Russell Investments Group, Ltd. | 8,001 | +4,027 (+101.33%) | 0.01% | $0 M | Nov 6, 2026 |
| 78 | Blue Trust, Inc. | 7,000 | 0 (0.00%) | 0.01% | $0 M | Oct 15, 2026 |
| 79 | Clearstead Advisors, LLC | 6,000 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 80 | Jones Financial Companies Lllp | 5,423 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 81 | Global Retirement Partners, LLC | 4,831 | +4,581 (+1832.40%) | 0.00% | $0 M | Nov 10, 2026 |
| 82 | Group One Trading LLC | 4,781 | -8,972 (-65.24%) | 0.00% | $0 M | Nov 10, 2026 |
| 83 | Legal & General Group Plc | 4,662 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 84 | Ameritas Investment Partners, Inc. | 4,349 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 85 | CoreCap Advisors, LLC | 3,890 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 86 | Tower Research Capital LLC (TRC) | 3,530 | -1,075 (-23.34%) | 0.00% | $0 M | Nov 16, 2026 |
| 87 | Royal Bank Of Canada | 2,824 | +1,192 (+73.04%) | 0.00% | $0 M | Nov 16, 2026 |
| 88 | Citigroup Inc | 2,363 | -20,105 (-89.48%) | 0.00% | $0 M | Nov 4, 2026 |
| 89 | Activest Wealth Management | 2,000 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 90 | Northwestern Mutual Wealth Management Co | 1,885 | -91 (-4.61%) | 0.00% | $0 M | Nov 13, 2026 |
| 91 | Sterling Capital Management LLC | 1,373 | +956 (+229.26%) | 0.00% | $0 M | Oct 22, 2026 |
| 92 | Hilton Head Capital Partners, LLC | 800 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 93 | Nisa Investment Advisors, LLC | 716 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 94 | California State Teachers Retirement System | 660 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 95 | Fortitude Family Office, LLC | 372 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 96 | Parkside Financial Bank & Trust | 260 | New | 0.00% | $0 M | Oct 27, 2026 |
| 97 | GAMMA Investing LLC | 166 | New | 0.00% | $0 M | Oct 8, 2026 |
| 98 | Jacobi Capital Management LLC | 125 | New | 0.00% | $0 M | Nov 5, 2026 |
| 99 | Allworth Financial LP | 89 | New | 0.00% | $0 M | Nov 17, 2026 |
| 100 | Arax Advisory Partners | 30 | New | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Galectin Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.52 M | $7 M | 1.5% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 951,470 | $4 M | 0.94% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 594,705 | $3 M | 0.59% | <0.01% | +5.5% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 520,365 | $2 M | 0.52% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 309,874 | $1 M | 0.31% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 160,592 | $1 M | 0.16% | 0.05% | +40% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 271,585 | $1 M | 0.27% | <0.01% | −1.8% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 112,988 | $1 M | 0.11% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 89,577 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 116,397 | $0 M | 0.12% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 95,489 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 48,031 | $0 M | 0.05% | <0.01% | +110% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 47,686 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 78,302 | $0 M | 0.08% | <0.01% | +5.8% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 63,710 | $0 M | 0.06% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 35,800 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 30,807 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 26,902 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 24,971 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 45,615 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 24,567 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 20,343 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 26,705 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 16,377 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 16,000 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 22,888 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 19,905 | $0 M | 0.02% | <0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 12,613 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 10,784 | $0 M | 0.01% | 0.02% | +26% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 10,158 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,960 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 7,501 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 7,224 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 6,110 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 6,042 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 5,600 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 5,600 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 8,649 | $0 M | <0.01% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 4,864 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,349 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,832 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 3,743 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 3,643 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 5,612 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 5,424 | $0 M | <0.01% | <0.01% | +4.1% | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 4,684 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 2,944 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,010 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 3,637 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 2,287 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,749 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 2,524 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,276 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,210 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 1,127 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 700 | $0 M | <0.01% | <0.01% | −36% | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 271 | $0 M | <0.01% | <0.01% | +8.8% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 57 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Galectin Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Richard E. UihleinDirector, 10% owner | Option exerciseindirect | +31.83 M | $3.000 | $95.5 M | 42.16 M | Form 4 |
| filed | Richard E. UihleinDirector, 10% owner | Option exerciseindirect | +2.55 M | $4.050 | $10.3 M | 44.71 M | Form 4 |
| filed | Khurram JamilChief Medical Officer | Option exercise10b5-1 plan | +16,250 | $3.040 | $49 K | 16,250 | Form 4 |
| filed | Khurram JamilChief Medical Officer | Sell10b5-1 plan | -16,250 | $5.130 | $83 K | 0 | Form 4 |
| filed | Harold H. ShlevinDirector | Option exercise10b5-1 plan | +22,268 | $1.230 | $27 K | 28,768 | Form 4 |
| filed | Harold H. ShlevinDirector | Sell10b5-1 plan | -22,268 | $5.040 | $112 K | 6,500 | Form 4 |
| filed | Khurram JamilChief Medical Officer | Option exercise10b5-1 plan | +47,467 | $2.500 | $119 K | 47,467 | Form 4 |
| filed | Khurram JamilChief Medical Officer | Sell10b5-1 plan | -47,467 | $5.040 | $239 K | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Galectin Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-06-20 13:43 UTC, code LUDP, resumed 13:48 UTC
- 2025-06-20 13:31 UTC, code LUDP, resumed 13:36 UTC
Fails to deliver
- : 5,567 shares at $3.54
- : 6,166 shares at $3.38
- : 10,478 shares at $3.19
- : 289 shares at $3.37
- : 21,077 shares at $3.43
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Galectin Therapeutics Inc. scorecard#
Passes 1 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-4.8%Free cash flow is -4.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.48 vs -0.76Diluted EPS -0.48 in fiscal 2025 against -0.76 the year before (report's currency).
- ✗Net income higher than five years earlier-$31 M-$31 M in fiscal 2025 against -$23 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$31 MNet income -$31 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.42 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year2.6%Diluted shares up 2.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Galectin Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 14−60.9%— | 37+13.8%— | 32+1.2%— | 32+33.2%— | 24+32.5%— | 18+141%— | 7.5+15.4%— | 6.5−44.8%— | 12−23.5%— | 15—— | |
| General and administrative | 5.8−1.1%— | 5.9−1.3%— | 5.9−10.2%— | 6.6+4.0%— | 6.4+16.3%— | 5.5−8.4%— | 6.0−16.3%— | 7.1+57.6%— | 4.5−26.5%— | 6.2—— | |
| Operating expenses | 20−52.7%— | 42+11.5%— | 38−0.7%— | 38+27.1%— | 30+28.7%— | 23+74.5%— | 13−1.2%— | 14−16.3%— | 16−24.4%— | 21—— | |
| Operating income | −20—— | −42—— | −38—— | −38—— | −30—— | −23—— | −13—— | −14—— | −16—— | −21—— | |
| Interest and finance income | 0.1−62.7%— | 0.3+47.0%— | 0.2+342%— | 0.1+1633%— | 0.0−95.5%— | 0.1−71.4%— | 0.2+508%— | 0.0+58.3%— | 0.0−46.7%— | 0.0—— | |
| Interest expense and finance costs | 7.3+32.3%— | 5.5+98.4%— | 2.8+170%— | 1.0+111%— | 0.5+462%— | 0.10.0%— | 0.1−74.1%— | 0.3+2700%— | 0.0—— | — | |
| Other non-operating income (expense) | −11—— | −4.6—— | −3.0—— | −0.4—— | −0.3—— | −0.0−115%— | 0.1—— | −0.3−2583%— | 0.0−73.3%— | 0.0—— | |
| Income tax | 0—— | 0—— | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −31—— | −47—— | −41—— | −39—— | −31—— | −23—— | −13—— | −14—— | −16—— | −21—— | |
| Earnings per share, basic | -0.48—— | -0.76—— | -0.74—— | -0.65—— | -0.52—— | -0.41—— | -0.39—— | -0.38—— | -0.49—— | -0.76—— | |
| Earnings per share, diluted | -0.48—— | -0.76—— | -0.74—— | -0.65—— | -0.52—— | -0.41—— | -0.39—— | -0.38—— | -0.49—— | -0.76—— | |
| Shares, weighted average (basic) | 64+2.6%— | 62+3.6%— | 60+1.3%— | 59+1.5%— | 59+2.6%— | 57—— | — | — | — | — | |
| Shares, weighted average (diluted) | 64+2.6%— | 62+3.6%— | 60+1.3%— | 59+1.5%— | 59+2.6%— | 57+9.2%— | 52+32.5%— | 39+11.0%— | 36+21.6%— | 29—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 18+17.2%90.7% | 15−41.1%86.4% | 26+38.0%91.0% | 19−53.1%87.3% | 40+46.1%94.8% | 27−42.8%91.7% | 47+475%98.0% | 8.3+170%91.6% | 3.1−80.1%73.4% | 15—97.3% | |
| Other current assets | 1.7−19.5%8.8% | 2.1+4.0%12.2% | 2.1+4.6%7.3% | 2.0−9.8%9.2% | 2.2−6.5%5.2% | 2.3+219%7.8% | 0.7+25.9%1.5% | 0.6−24.4%6.4% | 0.8+77.3%18.4% | 0.4—2.7% | |
| Current assets | 19+12.7%99.5% | 17−37.7%98.6% | 28+34.8%98.3% | 21−50.9%96.6% | 42+41.9%100.0% | 29−38.9%99.5% | 48+446%99.5% | 8.8+131%98.1% | 3.8−75.8%91.8% | 16r16—100.0% | |
| Property, plant and equipment | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Right-of-use (leased) assets | 0.0+37.5%0.1% | 0.0−65.2%0.1% | 0.0r0.1−46.5%0.2% | 0.1+1129%0.4% | 0.0—0.0% | — | — | — | — | — | |
| Other intangible assets | — | — | — | — | — | — | — | 0—0.0% | 0−100%0.0% | 0.0—0.0% | |
| Total assets | 20+11.6%100% | 17−38.0%100% | 28+32.5%100% | 21−49.1%100% | 42+41.3%100% | 30−38.9%100% | 48+438%100% | 9.0+116%100% | 4.2−73.7%100% | 16—100% | |
| Accounts payable | 3.2−42.6%16.6% | 5.7−12.1%32.3% | 6.4+65.3%22.8% | 3.9+116%18.3% | 1.8+39.7%4.3% | 1.3−22.2%4.4% | 1.7+459%3.4% | 0.3−51.2%3.3% | 0.6−33.2%14.6% | 0.9—5.8% | |
| Current liabilities | 8.0−77.3%41.1% | 35+126%202% | 16+20.5%55.6% | 13+44.0%61.1% | 9.0+67.3%21.6% | 5.4+91.5%18.2% | 2.8+33.8%5.8% | 2.1−29.0%23.4% | 3.0−21.5%71.3% | 3.8—23.9% | |
| Lease liabilities (non-current) | — | — | 0.0−69.7%0.1% | 0.1—0.3% | — | — | — | — | — | — | |
| Total liabilities | 146+20.9%746% | 121+36.3%689% | 88+65.4%314% | 53+36.4%251% | 39+625%93.7% | 5.4+88.3%18.3% | 2.9+36.2%5.9% | 2.1−29.0%23.4% | 3.0−21.5%71.3% | 3.8—23.9% | |
| Retained earnings | −433—−2215% | −402—−2295% | −354—−1257% | −310—−1454% | −271—−647% | −240—−811% | −216—−446% | −196—−2179% | −181—−4354% | −164—−1036% | |
| Shareholders' equity | −128—−655% | −105—−599% | −62—−220% | −34−3898%−159% | 0.9−96.0%2.1% | 22−48.8%75.9% | 44+748%90.5% | 5.2—57.5% | −0.5−105%−12.7% | 10—65.2% | |
| Total liabilities and equity | 20+11.6%100% | 17−38.0%100% | 28+32.5%100% | 21−49.1%100% | 42+41.3%100% | 30−38.9%100% | 48+438%100% | 9.0+116%100% | 4.2−73.7%100% | 16—100% | |
| Shares outstanding | 65+3.2%— | 63+2.1%— | 62+4.1%— | 59+0.1%— | 59+4.0%— | 57+0.3%— | 57+38.1%— | 41+15.1%— | 36+8.7%— | 33—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0−100%— | 0.0−85.7%— | 0.0—— | |
| Share-based compensation | 1.7−32.2%— | 2.4+8.2%— | 2.3−21.1%— | 2.9+38.1%— | 2.1+15.4%— | 1.8+6.9%— | 1.7−62.1%— | 4.4+304%— | 1.1−55.6%— | 2.5—— | |
| Cash from operating activities | −24—— | −42—— | −33—— | −31—— | −24—— | −21—— | −11—— | −10—— | −16—— | −16—— | |
| Cash from investing activities | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | — | 0—— | 0—— | 0—— | |
| Shares issued | 3.2—— | 0—— | — | 0−100%— | 6.8+2491%— | 0.3−99.5%— | 50+228%— | 15+329%— | 3.6−39.5%— | 5.9—— | |
| Cash from financing activities | 26−15.2%— | 31−22.0%— | 40+300%— | 10−72.8%— | 37+13898%— | 0.3−99.5%— | 50+226%— | 15+329%— | 3.6−39.5%— | 5.9—— | |
| Change in cash | — | — | — | — | — | — | — | 5.2—— | −12—— | −10—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 8.9−68.7%— | 2.1−34.5%— | 2.2−65.6%— | 1.9*−82.6%— | 2.6−65.6%— | 3.3−66.8%— | 6.5−19.5%— | 11*+35.0%— | 7.6−1.8%— | 9.8—— | 8.1—— | 8.2*—— | 7.7—— | |
| General and administrative | 6.7+20.6%— | 1.8+35.4%— | 1.8+30.7%— | 1.4*+8.6%— | 1.6+7.9%— | 1.4−7.7%— | 1.4−11.4%— | 1.3*−1.1%— | 1.5+2.6%— | 1.5—— | 1.6—— | 1.3*—— | 1.4—— | |
| Operating expenses | 16−54.1%— | 4.0−13.9%— | 4.1−48.4%— | 3.4*−72.9%— | 4.2−53.7%— | 4.6−59.0%— | 7.9−18.1%— | 12*+30.0%— | 9.1−1.1%— | 11—— | 9.6—— | 9.6*—— | 9.2—— | |
| Operating income | −16—— | −4.0—— | −4.1—— | −3.4*—— | −4.2—— | −4.6—— | −7.9—— | −12*—— | −9.1—— | −11—— | −9.6—— | −9.6*—— | −9.2—— | |
| Interest and finance income | 0.1−46.2%— | 0.0+7.7%— | 0.0+2.9%— | 0.0*−70.2%— | 0.0−58.1%— | 0.0−67.5%— | 0.0−56.3%— | 0.1*+13.5%— | 0.1+50.0%— | 0.1—— | 0.1—— | 0.1*—— | 0.1—— | |
| Interest expense and finance costs | 7.8+14.2%— | 2.0+9.7%— | 2.0+14.0%— | 1.9*+12.4%— | 1.8+21.8%— | 1.8+43.9%— | 1.7+65.8%— | 1.7*+104%— | 1.5+78.9%— | 1.3—— | 1.1—— | 0.8*—— | 0.8—— | |
| Other non-operating income (expense) | −12—— | −5.1—— | −1.0—— | −2.1*−563%— | −4.0—— | −2.9—— | −1.7—— | 0.5*—— | −2.2—— | −1.1—— | −1.8—— | −0.4*—— | −1.3—— | |
| Net income attributable to shareholders | −28—— | −9.1—— | −5.0—— | −5.5*—— | −8.2—— | −7.5—— | −9.6—— | −12*—— | −11—— | −12—— | −11—— | −10.0*—— | −10—— | |
| Earnings per share, basic | — | -0.14—— | -0.08—— | — | -0.13—— | -0.12—— | -0.15—— | — | -0.18—— | -0.20—— | -0.19—— | — | -0.24—— | |
| Earnings per share, diluted | — | -0.14—— | -0.08—— | — | -0.13—— | -0.12—— | -0.15—— | — | -0.18—— | -0.20—— | -0.19—— | — | -0.24—— | |
| Shares, weighted average (basic) | 66+3.8%— | 66+3.8%— | 66+4.1%— | — | 64+3.1%— | 63+2.0%— | 63+2.0%— | — | 62+4.3%— | 62—— | 62—— | — | 60—— | |
| Shares, weighted average (diluted) | 66+3.8%— | 66+3.8%— | 66+4.1%— | — | 64+3.1%— | 63+2.0%— | 63+2.0%— | — | 62+4.3%— | 62—— | 62—— | — | 60—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 13—89.5% | 13−3.6%89.5% | 14+89.9%89.5% | 18+17.2%90.7% | 12−57.4%89.6% | 14−46.2%88.3% | 7.4−68.5%78.0% | 15−41.1%86.4% | 27+32.9%93.4% | 26—92.6% | 24—91.0% | 26—91.0% | 20—91.9% | |
| Other current assets | 1.4—9.4% | 1.4−16.1%9.4% | 1.6−14.8%10.0% | 1.7−19.5%8.8% | 1.2−25.0%9.4% | 1.7−2.0%10.6% | 1.9−2.7%19.5% | 2.1+4.0%12.2% | 1.6+28.6%5.5% | 1.7—6.1% | 1.9—7.4% | 2.1—7.3% | 1.2—5.6% | |
| Current assets | 15—98.9% | 15−5.0%98.9% | 16+69.0%99.6% | 19+12.7%99.5% | 13−55.6%98.9% | 15−43.5%98.9% | 9.3−63.5%97.4% | 17−37.7%98.6% | 29+32.6%98.9% | 27—98.7% | 25—98.3% | 28—98.3% | 22—97.5% | |
| Property, plant and equipment | — | — | — | 0—0.0% | — | — | — | 0—0.0% | — | — | — | 0—0.0% | — | |
| Right-of-use (leased) assets | 0.1—0.8% | 0.1+127%0.8% | 0.0−90.9%0.0% | 0.0+37.5%0.1% | 0.0+42.3%0.3% | 0.1+48.6%0.3% | 0.1+46.7%0.7% | 0.0−65.2%0.1% | 0.0−58.1%0.1% | 0.0—0.1% | 0.0—0.2% | 0.0r0.1—0.2% | 0.1—0.3% | |
| Total assets | 15—100% | 15−5.0%100% | 16+65.4%100% | 20+11.6%100% | 13−55.6%100% | 16−43.6%100% | 9.5−63.2%100% | 17−38.0%100% | 29+30.7%100% | 28—100% | 26—100% | 28—100% | 22—100% | |
| Accounts payable | 3.7—25.1% | 3.7−36.5%25.1% | 3.1−52.2%19.8% | 3.2−42.6%16.6% | 5.4+92.8%41.9% | 5.9+58.6%37.6% | 6.5+72.1%68.6% | 5.7−12.1%32.3% | 2.8+4.3%9.6% | 3.7—13.4% | 3.8—14.7% | 6.4—22.8% | 2.7—12.1% | |
| Current liabilities | 152—1023% | 152+1307%1023% | 7.3−93.4%46.4% | 8.0−77.3%41.1% | 136+440%1061% | 11−26.3%69.1% | 111+777%1163% | 35+126%202% | 25+140%87.2% | 15—52.9% | 13—48.8% | 16—55.6% | 11—47.5% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | — | — | 0.0—0.0% | 0.0—0.1% | 0.0—0.1% | |
| Total liabilities | 152—1023% | 152+14.2%1023% | 146+19.9%926% | 146+20.9%746% | 136+12.3%1061% | 133+20.9%851% | 122+25.6%1278% | 121+36.3%689% | 121+66.3%419% | 110—397% | 97—375% | 88—314% | 73—330% | |
| Retained earnings | −447—−3014% | −447—−3014% | −438—−2777% | −433—−2215% | −427—−3319% | −419—−2684% | −411—−4315% | −402—−2295% | −390—−1345% | −378—−1368% | −366—−1413% | −354—−1257% | −344—−1554% | |
| Shareholders' equity | −139—−935% | −139—−935% | −132—−837% | −128—−655% | −125—−974% | −119—−762% | −114—−1196% | −105—−599% | −94—−325% | −84—−303% | −44r−73—−171% | −62—−220% | −53—−237% | |
| Total liabilities and equity | 15—100% | 15−5.0%100% | 16+65.4%100% | 20+11.6%100% | 13−55.6%100% | 16−43.6%100% | 9.5−63.2%100% | 17−38.0%100% | 29+30.7%100% | 28—100% | 26—100% | 28—100% | 22—100% | |
| Shares outstanding | 66—— | 66+3.5%— | 66+4.1%— | 65+3.2%— | 64+3.5%— | 64+2.9%— | 63+1.8%— | 63+2.1%— | 62+0.7%— | 62—— | 62—— | 62—— | 62—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.3+13.0%— | 1.0+92.6%— | 0.7+46.6%— | 0.2*−66.9%— | 0.5−3.3%— | 0.5−32.2%— | 0.5−22.5%— | 0.6*+18.7%— | 0.5−12.1%— | 0.7r0.7—— | 0.6—— | 0.5*—— | 0.6—— | |
| Cash from operating activities | −16—— | −2.4*—— | −3.9—— | −6.0*—— | −3.5*—— | −6.6*—— | −7.7—— | −13*—— | −8.5*—— | −8.3*—— | −12—— | −4.7*—— | −7.6*—— | |
| Shares issued | — | — | — | 1.2*—— | 0.9*—— | — | — | 0*—— | 0*—— | — | — | — | — | |
| Cash from financing activities | 15−35.3%— | 1.6*−87.7%— | 0.3—— | 12*+1338%— | 1.3*−87.0%— | 13*+24.7%— | 0−100%— | 0.9*−91.5%— | 10*−0.3%— | 10*—— | 10—— | 10*—— | 10*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Galectin Therapeutics Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Joel Lewis | $1.2 M | $1.7 M | $929 K | $322 |
| 2024Joel Lewis | $1.2 M | $1.1 M | $831 K | $78 |
| 2023Joel Lewis | $964 K | $1.1 M | $666 K | $147 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Galectin Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 2 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 14, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Galectin Therapeutics Inc. compares in Biotechnology
- Market cap$357 M · higher than 54% of 726
- FCF yield-4.8% · higher than 73% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Galectin Therapeutics Inc.🇺🇸 | $357 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Galectin Therapeutics Inc.? Verify and update this profile — free
Show Galectin Therapeutics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.